Volume | 53,556 |
|
|||||
News | - | ||||||
Day High | 0.029 | Low High |
|||||
Day Low | 0.0167 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Nexien BioPharma Inc (QB) | NXEN | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.029 | 0.0167 | 0.029 | 0.0167 | 0.0163 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4 | 53,556 | $ 0.028481 | $ 1,525 | - | 0.011 - 0.0998 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:22:03 | 2,954 | $ 0.0167 | USD |
Nexien BioPharma Inc (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.27M | 64.02M | 11.59M | 0 | -362k | -0.01 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Nexien BioPharma (QB) News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NXEN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.0168 | 0.029 | 0.0163 | 0.0167916 | 14,590 | -0.0001 | -0.60% |
1 Month | 0.02026 | 0.029 | 0.0163 | 0.0183769 | 8,980 | -0.00356 | -17.57% |
3 Months | 0.01954 | 0.03 | 0.0151 | 0.0215318 | 10,583 | -0.00284 | -14.53% |
6 Months | 0.029 | 0.04 | 0.011 | 0.0225762 | 11,685 | -0.0123 | -42.41% |
1 Year | 0.04055 | 0.0998 | 0.011 | 0.0283332 | 10,425 | -0.02385 | -58.82% |
3 Years | 0.12 | 0.195 | 0.011 | 0.0770308 | 15,613 | -0.1033 | -86.08% |
5 Years | 0.08 | 0.445 | 0.0085 | 0.1149939 | 26,749 | -0.0633 | -79.13% |
Nexien BioPharma (QB) Description
Nexien BioPharma Inc. is a US-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals, in accordance with U.S. Food and Drug Administration ('FDA') pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders. Nexien BioPharma's drug development strategy consists of: A. The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations; B. Conducting "freedom to operate" investigations on these conditions; C. The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents; D. Identifying the regulatory pathway with the FDA; and E. Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s). |